Literature DB >> 27757161

When conventional treatment fails: the role of intravenous immunoglobulin in recurrent pregnancy loss secondary to antiphospholipid syndrome.

Jacklyn Chay1, Karin Lust2, Paul Kubler2, Leonie Callaway2.   

Abstract

Recurrent pregnancy loss (RPL) is a well-recognized complication of antiphospholipid syndrome (APS). First line therapy consists of low dose aspirin and heparin. Despite conventional therapy some women fail to achieve a successful pregnancy outcome. We describe the case of a patient who had two live births following intravenous immunoglobulin therapy despite previous failure with conventional therapy for RPL in the setting of APS. We will summarize the available literature on intravenous immunoglobulin for this indication.

Entities:  

Keywords:  IVIG; antiphospholipid syndrome; recurrent pregnancy loss

Year:  2013        PMID: 27757161      PMCID: PMC5052759          DOI: 10.1177/1753495X12472644

Source DB:  PubMed          Journal:  Obstet Med        ISSN: 1753-495X


  27 in total

Review 1.  Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin.

Authors:  M D Kazatchkine; S V Kaveri
Journal:  N Engl J Med       Date:  2001-09-06       Impact factor: 91.245

Review 2.  The therapeutic uses of intravenous immunoglobulins in autoimmune rheumatic diseases.

Authors:  D Pyne; M Ehrenstein; V Morris
Journal:  Rheumatology (Oxford)       Date:  2002-04       Impact factor: 7.580

3.  Efficacy and safety of two doses of low molecular weight heparin (enoxaparin) in pregnant women with a history of recurrent abortion secondary to antiphospholipid syndrome.

Authors:  U M Fouda; A M Sayed; D I Ramadan; I M Fouda
Journal:  J Obstet Gynaecol       Date:  2010       Impact factor: 1.246

4.  Obstetric antiphospholipid syndrome: current uncertainties should guide our way.

Authors:  D W Branch; R M Silver; T F Porter
Journal:  Lupus       Date:  2010-04       Impact factor: 2.911

Review 5.  Intravenous immunoglobulin in antiphospholipid syndrome and maternal floor infarction when standard treatment fails: a case report.

Authors:  Phyllis Chang; Debra Millar; Peter Tsang; Kenneth Lim; Edwina Houlihan; Mary Stephenson
Journal:  Am J Perinatol       Date:  2006-02       Impact factor: 1.862

Review 6.  Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant.

Authors:  M Empson; M Lassere; J Craig; J Scott
Journal:  Cochrane Database Syst Rev       Date:  2005-04-18

Review 7.  IVIG in APS pregnancy.

Authors:  G Triolo; A Ferrante; A Accardo-Palumbo; F Ciccia; M Cadelo; A Castelli; A Perino; G Licata
Journal:  Lupus       Date:  2004       Impact factor: 2.911

Review 8.  Combination of heparin and aspirin is superior to aspirin alone in enhancing live births in patients with recurrent pregnancy loss and positive anti-phospholipid antibodies: a meta-analysis of randomized controlled trials and meta-regression.

Authors:  Anselm Mak; Mike W-L Cheung; Alicia Ai-cia Cheak; Roger Chun-Man Ho
Journal:  Rheumatology (Oxford)       Date:  2009-12-04       Impact factor: 7.580

9.  Intravenous immunoglobulin therapy in pregnant patients affected with systemic lupus erythematosus and recurrent spontaneous abortion.

Authors:  R Perricone; C De Carolis; B Kröegler; E Greco; R Giacomelli; P Cipriani; L Fontana; C Perricone
Journal:  Rheumatology (Oxford)       Date:  2008-03-17       Impact factor: 7.580

10.  Normal fetal growth in women with antiphospholipid syndrome treated with high-dose intravenous immunoglobulin (IVIG).

Authors:  H Valensise; E Vaquero; C De Carolis; E Stipa; R Perricone; D Arduini; C Romanini
Journal:  Prenat Diagn       Date:  1995-06       Impact factor: 3.050

View more
  1 in total

1.  Combined detection of anticardiolipin and anti-β2-glycoprotein 1 antibodies may predict pregnancy outcome.

Authors:  Rongjuan Yang; Jiajia Zhang; Limei Zhang; Yongli Liu; Qing Guo
Journal:  Am J Transl Res       Date:  2022-03-15       Impact factor: 4.060

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.